01:17 , Jun 29, 2019 |  BC Extra  |  Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of the company's founders, who will become executive entrepreneur and an adviser to the board. Pearson, who was...
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
23:15 , Dec 7, 2018 |  BioCentury  |  Emerging Company Profile

ADCendo: entering tumors via MRC2

ADCendo ApS is developing an antibody-drug conjugate against mannose receptor C type 2 (MRC2; UPARAP) that could treat cancers at lower doses and with less toxicity than other ADCs, due to the target’s enriched cancer...
23:08 , Nov 28, 2018 |  BC Innovations  |  Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
23:03 , Oct 2, 2018 |  BC Extra  |  Politics & Policy

Nobel Prize goes to discoverers of checkpoint targets

Discoveries that led to a pair of first-in-world approvals for two blockbuster cancer drugs from Bristol-Myers Squibb Co. (NYSE:BMY) and touched off a new era in treating cancer were the focus of this year's Nobel...
23:21 , Sep 10, 2018 |  BC Extra  |  Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
17:54 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro , cell culture and mouse studies identified two benzenesulfonamide-based AXL inhibitors that could help treat breast cancer. Chemical synthesis and in vitro enzymatic activity assays of benzenesulfonamide analogs yielded two...
23:34 , Jan 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
16:03 , Jan 15, 2018 |  BC Extra  |  Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

In a study published in Nature Medicine , Genmab A/S (CSE:GEN; Pink:GMXAY) and academic researchers identified a combination therapy approach that could combat drug resistance in heterogeneous tumors. Melanoma tumors with BRAF mutations that are...
20:23 , May 26, 2017 |  BC Week In Review  |  Company News

BioAtla, Beijing Sinobioway expand CAB deal

BioAtla LLC (San Diego, Calif.) and Beijing Sinobioway Group Ltd. (Beijing, China) added five products from BioAtla's Conditionally Active Biologic (CAB) platform to a 2015 deal granting Sinobioway exclusive rights to develop and commercialize similar...